Who is the CEO of Nicox S.A.?

Dr. Michele Garufi Ph.D. is a business executive who currently serves as the CEO of Nicox S.A..

What is the Revenue Growth of Nicox S.A.?

Revenue growth data for Nicox S.A. is currently unavailable.

What is Nicox S.A. operating Margin?

Nicox S.A. operating margin is -413.89% which shows how much profit COX.PA earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Nicox S.A. operate?

Nicox S.A. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Nicox S.A. revenue growth?

Revenue growth data for Nicox S.A. is currently unavailable.

Nicox S.A.

COX.PA•EURONEXT

HealthcareBiotechnology

$0.58

$0.00(0.00%)

Nicox S.A. (COX.PA) Stock Overview

Explore Nicox S.A.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for COX.PAStats details for COX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for COX.PAAnalyst Recommendations details for COX.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.

CEO

Dr. Michele Garufi Ph.D.

Employees

Headquarters

2405 Route Des Dolines Drakkar D, Valbonne

Founded

1999